Fidelity Select Portfolios - Medical Technology and Devices Portfolio (FSMEX) focuses on investing in companies within the medical technology and devices sector, which includes firms involved in the development and manufacturing of medical devices, diagnostics, and related technologies. The portfolio's competitive position is bolstered by Fidelity's extensive research capabilities and access to a broad range of medical technology firms across North America and Europe.
FSMEX generates revenue primarily through management fees charged on assets under management (AUM) and performance fees based on the fund's returns relative to benchmarks. The fund's competitive advantages include Fidelity's brand reputation, extensive research capabilities, and a diversified portfolio of high-growth medical technology firms.
Changes in healthcare regulations affecting medical device approvals
Mergers and acquisitions activity within the medical technology sector
Advancements in medical technology impacting the competitive landscape
Market sentiment towards healthcare spending trends
Regulatory changes that could impact the approval process for medical devices
Technological disruption from emerging health tech startups
Intensifying competition from established medical device companies and new entrants
Market share loss to innovative technologies and alternative therapies
Potential liquidity issues if significant fund outflows occur
Market volatility impacting asset valuations
moderate - The medical technology sector is somewhat insulated from economic downturns, but overall healthcare spending can be affected by GDP growth and consumer spending.
Interest rates can impact the cost of capital for medical technology firms, affecting their growth and investment strategies. Higher rates may reduce valuations and demand for growth-oriented investments.
minimal - The portfolio is not heavily reliant on credit markets, as it primarily invests in equities.
growth - Investors looking for exposure to high-growth medical technology firms.
moderate - The fund may experience volatility in line with the broader healthcare sector.